Chartwell Investment Partners’s Viking Therapeutics VKTX Stock Holding History

Chartwell Investment Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.32M	Buy	36,666 +17,159	+88%	+$1.01M	0.08%	276
2024 Q2	$1.03M	Sell	19,507 -12,056	-38%	-$790K	0.04%	345
2024 Q1	$2.59M	Sell	31,563 -22,906	-42%	-$1.02M	0.09%	264
2023 Q4	$1.01M	Sell	54,469 -7,350	-12%	-$96.1K	0.04%	354
2023 Q3	$685K	Hold	61,819	–	–	0.03%	376
2023 Q2	$1M	Buy	61,819 +10,491	+20%	+$220K	0.04%	353
2023 Q1	$854K	Sell	51,328 -36,514	-42%	-$377K	0.03%	357
2022 Q4	$826K	Buy	+87,842	New	+$392K	0.03%	360

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Chartwell Investment Partners's VKTX Position: Q3 2024 in Review

Chartwell Investment Partners increased its Viking Therapeutics (VKTX) stake by 88% in Q3 2024, buying an estimated $1.01M and bringing the position to 36,666 shares worth $2.32M. The position accounts for 0.08% of the portfolio, ranked #276.

Chartwell Investment Partners first reported a position in VKTX in Q4 2022 and has held it in 8 quarters since. The position peaked at $2.59M in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

Chartwell Investment Partners held 36,666 shares of Viking Therapeutics worth $2.32M as of Q3 2024.
Chartwell Investment Partners bought 17,159 Viking Therapeutics shares in Q3 2024, an estimated $1.01M.
Viking Therapeutics made up 0.08% of Chartwell Investment Partners's portfolio in Q3 2024, its #276 holding.
Chartwell Investment Partners first reported a position in Viking Therapeutics in Q4 2022 and has held it in 8 quarters since.
Chartwell Investment Partners's Viking Therapeutics position peaked at $2.59M in Q1 2024.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.